Company

UCI therapeutics

UCI therapeutics develops CAR-NK cell therapies and related cancer treatment technologies.

About

Founded in Pohang in 2020, UCI therapeutics develops cancer cell therapies using chimeric antigen receptor natural killer cells and its CellTaCT platform. In May 2022, it raised KRW 4.2 billion in pre-Series A funding from Colopl Next, DT&Investment, Gyeongnam Venture Investment, PathfinderH, POSCO Capital, SEMA Translink Investment, Seoul Business Agency, and Smilegate Investment.

1Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in